Abstract The burden of diabetes is increasing globally. Identifying novel preventable risk factors is an urgent need. In 2011, the U.S. National Toxicological Program (NTP) conducted a workshop to evaluate the epidemiologic and experimental evidence on the relationship of environmental chemicals with obesity, diabetes, and metabolic syndrome. Although the evidence was insufficient to establish causality, the NTP workshop review identified an overall positive association between some environmental chemicals and diabetes. In the present systematic review, our objective was to summarize the epidemiological research published since the NTP workshop. We identified a total of 29 articles (7 on arsenic, 3 on cadmium, 2 on mercury, 11 on persistent organic pollutants, 3 on phthalates, and 4 on bisphenol A), including 7 prospective studies. Considering consistency, temporality, strength, dose-response relationship, and biological plausibility (confounding), we concluded that the evidence is suggestive but not sufficient for a relationship between arsenic and persistent organic pollutants and is insufficient for mercury, phthalates, and bisphenol A. For cadmium, the epidemiologic evidence does not seem to suggest an association with diabetes. Important research questions include the need for additional prospective studies and the evaluation of the dose-response relationship, the role of joint exposures, and effect modification with other comorbidities and genetic variants.
obesity, diabetes, and metabolic syndrome (see the summary for diabetes in Table 1 ) [10•] .
In reviewing the available evidence, the NTP considered consistency across populations, strength and temporality of the associations, and biological plausibility, including extensive evaluation of the animal and mechanistic evidence. In addition to a report of the workshop review, several publications have summarized the findings of the NTP workshop review [11] , including an overall paper for all the chemicals evaluated [10•] and specific papers for arsenic [12•] , persistent organic pollutants (POPs) [13•] , and maternal smoking [14] . Since the NTP workshop review, interest in the potential role of environmental chemicals in diabetes has continued to increase. In the present review, we used the NTP workshop review as a starting point (Table 1 ) and updated the new evidence available on the association between diabetes and the following environmental chemicals: arsenic, other metals, POPs, phthalates, and bisphenol A (BPA). For organotins, no new epidemiological studies have been published. Other environmental exposures with increasing evidence available to assess a potential association with diabetes, such as exposure to tobacco smoke [15] and air pollution [16, 17] , will not be evaluated in the present review.
Method
The systematic search and review processes were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement criteria, although the quality of the evidence and the risk of bias were not specifically evaluated in the present review [18] . To update the NTP workshop review, we searched MEDLINE for epidemiological studies investigating the association between those environmental chemicals and diabetes, using the search strategy described in Table 2 . The search period was January 1966 through May 2013. There were no language restrictions. We also manually reviewed the reference lists from relevant original research and the investigators' files. Our exclusion criteria were (1) publications containing no original research (reviews, editorials, nonresearch letters), (2) studies not carried out in humans, (3) exposures not measured at the individual level (e.g., ecological studies or studies measuring the chemical of interest at the community level), (4) case reports and case series, (5) studies not reporting the association between environmental chemicals and diabetes, and (6) studies previously reviewed by the NTP workshop review (Fig. 1) . Two authors, C. C. Kuo and K. Moon, independently abstracted data from the articles that met the selection criteria. We collected the following data for each study: authors, journal, year of publication, country, study design, study population, exposure assessment, diabetes diagnosis, measures of association, adjustment factors, and other critical comments. For studies modeling chemical exposures both as continuous and as categorical, we reported categorical measures of association in order to allow for a more flexible evaluation of the dose-response relationship. For POPs, when multiple congeners were reported, we selected the congener with the weakest association, the congener with the maximum association, and the congener with the median association. Disagreement was resolved by discussion between the two review authors, and if necessary, a third reviewer was involved.
Following the criteria proposed by the Office of Health Assessment and Translation (OHAT) at the National Toxicology Program (NTP) and similar criteria proposed by the 2004 Surgeon General Report on the health consequences of smoking [19, 20] , we evaluated consistency, temporality, strength, dose-response relationship, and biological plausibility (confounding) of the findings. Following this evaluation, we classified the evidence for each environmental chemical and diabetes in four groups as modified from the Surgeon General Report [19] : sufficient evidence, suggestive but not sufficient evidence, insufficient evidence to infer a relationship, and suggestive of no relationship. Similar categories have been proposed by OHAT: high level of evidence, moderate level of evidence, low level of evidence, and not classifiable [20] .
Arsenic and Diabetes

Current Perspectives
Inorganic arsenic in water and food are major global health problems [21, 22] . The toxicity and carcinogenicity of inorganic arsenic is well established [23, 24] . In recent years, increasing epidemiologic evidence from multiple countries supports the role of inorganic arsenic in the development of diabetes [25] [26] [27] [28] [29] [30] . Experimental and mechanistic evidence provide additional support for arsenic diabetogenesis [31] [32] [33] . Arsenic could affect β-cell function and insulin sensitivity through several mechanisms, including oxidative stress, glucose uptake and transport, gluconeogenesis, adipocyte differentiation, and calcium signaling [12•, 34-36] . Arsenic could also act as an endocrine disrupter affecting the function of hormone receptors, including glucocorticoid, androgen, estrogen, and thyroid hormone in cell culture and animal models [31, 32, 37] . Finally, arsenic could also impact diabetes through epigenetic mechanisms, including hyper-and hypo-methylation of diabetesrelated genes [38, 39] .
In its evaluation of the association between arsenic and diabetes, the NTP workshop review distinguished between studies conducted in populations exposed to high arsenic levels in drinking water (≥150 μg/L) and studies conducted in populations exposed to low-moderate arsenic levels in drinking water (<150 μg/L) ( Table 1 ). The NTP workshop review concluded that at high-chronic exposure levels, the DDD dichlorodiphenyldichloroethane; DDE dichlorodiphenyldichloroethane; DDT dichlorodiphenyltrichloroethane; HOMA homeostatic model assessment; NR not reported; PCBs polychlorinated biphenyls; PFAAs perfluoroalkyl acids; POPs persistent organic pollutants; TCDD tetrachlorodibenzo-p-dioxin *High arsenic and low-moderate arsenic levels were defined as ≥ and <150 μg/L in drinking water, respectively **Includes studies that report only no. of deaths rather than total number of subjects -Indicates not reported in the NTP report epidemiological evidence was "limited to sufficient" to support the association between arsenic and diabetes. The studies at high levels of exposure, conducted in Taiwan and Bangladesh, were mostly consistent with an association between arsenic and diabetes. Despite the consistency in the findings, however, the level of evidence was considered "limited to sufficient" and not "sufficient," because most studies were cross-sectional, arsenic exposure was rarely measured at the individual level, and some studies lacked appropriate definitions of diabetes and adjustment for confounders. At levels of arsenic in drinking water <150 μg/L, the NTP review concluded that the evidence was "insufficient" to conclude that arsenic is associated with diabetes, because the findings were inconsistent and most studies were characterized by limited exposure and outcome assessment. All studies at lowmoderate levels of exposure at the time of the NTP review were cross-sectional. A total of seven studies meeting our inclusion criteria have been published following the NTP workshop in 2011, all of them in populations exposed to low-moderate arsenic levels in drinking water (Table 3 ). The studies were conducted in populations from Korea [40] , Bangladesh [41] , Cyprus [42] , the United States [43] [44] [45] , and China [46] . Five studies were cross-sectional [40] [41] [42] [43] 46] , and two studies were prospective in design [44, 45] . Arsenic exposure was measured in drinking water at the household level in four studies [41, 42, 44, 46] and in urine in two studies from the U.S. and one study from South Korea [40, 43, 45] . Diabetes was defined by self-report [42] or by combining self-reported physician diagnosis [40, 41, 44, 46] and/or medication use [40, 43, 46] with, at least, fasting blood glucose (FBG) level [40, 41, 43, 44, 46] , oral glucose tolerance test (OGTT) [43] [44] [45] , or glycated hemoglobin (HbA1c) [43] (Table 3 ). All studies found a positive association between arsenic and diabetes, although only five of the associations were statistically significant (Table 3) . Estimated relative risks comparing the highest versus lowest arsenic exposure category ranged from 1.31 [40] to 1.90 [41] (median 1.55 [43] ). The two studies that found no significant association between arsenic and diabetes were conducted in Cyprus (414 participants) and China (669 participants) [42, 46] . The study from South Korea measured only total arsenic in urine, limiting the interpretation of The number in the brackets after each chemical is the number of articles identified based on a chemical-specific search strategy after combining the search strategy for this chemical with the search strategy for diabetes (#7) the study findings due to high seafood intake in the study population. The two prospective studies (nested case-control and case-cohort studies) were conducted in populations from the U.S. and found an association between arsenic and diabetes [44, 45] . These prospective studies provide critical evidence in support of the temporality criterion for causality. For future analyses, the consistency across populations in the two prospective studies and the four crosssectional studies that report information in multiple categories of exposure could potentially facilitate the evaluation of the dose-response relationship through the use of doseresponse meta-analyses. Overall, the evidence is suggestive but not sufficient to infer a causal relationship between inorganic arsenic exposure and diabetes at low-moderate levels of exposure. The major limitation is the small number and limited sample size of prospective studies.
Research Needs-Epidemiologic Studies
Additional prospective studies at low-moderate levels of arsenic exposure through drinking water and food are needed to confirm the potential role of inorganic arsenic in diabetes development. It is also important to characterize pathways for diabetogenesis, including measures of insulin resistance and pancreatic ß-cell function. Insulin resistance has been evaluated in several human studies with no evidence of an association [43, 51] , but pancreatic ß-cell function has not yet been evaluated. With the increasing awareness of arsenic in food and of the importance of food as a source of arsenic, using biomarkers to estimate arsenic exposure is critical. Urine arsenic, including arsenic species, is the most widely use biomarker of inorganic arsenic exposure. Urine arsenic speciation also allows for the analysis of arsenic metabolism. Limitations of arsenic in urine include accounting for urine dilution and accounting for organic arsenicals of seafood origin. Arsenic speciation, moreover, is expensive and technically time-consuming. Developing advanced technology to measure arsenic efficiently should also be a research priority.
Cadmium, Mercury, and Diabetes
Current Perspectives
Both cadmium and mercury are widespread in the environment and persistent in the food chain [52, 53] . Cadmium and mercury can induce hyperglycemia by altering pancreatic β-cell function via several pathways in experimental studies [54] [55] [56] . At the time of the 2011 NTP workshop, very little human data were available linking metals other than arsenic with diabetes. For cadmium, a positive association between cadmium and diabetes in the National Health and Nutrition Examination Survey (NHANES III) was published in 2003 [57] . We have identified three additional publications investigating the association between cadmium and diabetes (Table 3) . These studies were conducted in Thailand [47] , Sweden [48] , and South Korea [49] . Cadmium exposure was measured in urine [47] , blood [49] , or both blood and urine [48] . Diabetes was defined on the basis of self-reported physician diagnosis and/or medication use [47, 49] plus FBG [47] [48] [49] or OGTT [48] . All studies were cross-sectional, although one study also conducted a prospective investigation over 5.4 years of follow-up [48] . None of them supported the possibility that cadmium exposure, as measured in blood and urine, contributes to the development of diabetes [47] [48] [49] . There is evidence from animal studies that cadmium can induce hyperglycemia and pancreatic toxicity [56] ; however, additional work is needed to better understand the relevance of the dose levels and routes of administration used in experimental studies in the context of human exposure.
For mercury, two epidemiologic studies in the past year have evaluated its association with diabetes (Table 3 ) [49, 50•] . The studies were conducted in young adults from four U.S. cities [50•] and in a nationally representative sample of adults from South Korea [49] . Mercury exposure was measured in toenails [50•] and blood [49] . The South Korean study was cross-sectional, measured mercury in blood, and defined diabetes on the basis of self-reported diagnosis, antidiabetic medication use, or FBG. The study did not support the possibility that mercury was associated with the prevalence of diabetes. The U.S. study was prospective and defined incident diabetes over 18 years of follow-up on the basis of FBG, OGTT, or HbA1c. The hazard ratio for diabetes comparing the highest with the lowest toenail mercury quintiles was 1.65 [95 % CI: 1.07-2.56] [50•]. While additional prospective studies are needed to evaluate the consistency of the association, this prospective study supports the possible role of mercury in diabetes development. Overall, however, the evidence is insufficient to infer an association between arsenic and mercury.
Research Needs-Epidemiologic Studies
Since the NTP workshop, all recent reports have failed to confirm an association between cadmium and diabetes. Given these findings, initiating large-scale prospective studies might not be a current research priority. The only epidemiologic study that has found an association between cadmium and diabetes was conducted in NHANES III [57] . Since NHANES data are publically available, it will be important to replicate those analyses to confirm the findings in NHANES III, as well as to evaluate the association in NHANES 1999+.
For mercury, additional prospective studies are needed to evaluate the association with diabetes. Since the major sources of mercury in humans come from methylmercury exposure from seafood consumption [58] , adjustments for nutrients (e.g., selenium, magnesium, n-3 fatty acids), lifestyle (seafood as marker of healthy diet), and other toxicants in seafood (POPs) represent important challenges. The most recent meta-analyses on seafood and diabetes found no association between seafood consumption and the risk of diabetes [59] . However, mercury exposure was not considered in any of the primary studies. Overall, well-designed prospective studies are warranted to evaluate the joint effect between mercury and other nutrients and toxicants and its impact on the risk of diabetes. Finally, how to appropriately evaluate joint effects across multiple metals that are potentially diabetogenic remains controversial. Methods development for handling multiexposures is critical.
Persistent Organic Pollutants and Diabetes
Current Perspectives
Humans have been extensively exposed to synthetic chemicals since World War II [60] . Of the human-made chemicals, POPs may be the most widely distributed, since they are semivolatile, highly lipophilic, and resistant to photolytic, biological, and chemical degradation. POPs bioaccumulate in adipose tissues of both humans and wildlife, as well as in the food chain. They have a half-life ranging from months to years [61, 62] . Although POP refers to a broad class of compounds, priority pollutants consist of pesticides (such as chlordane and dichlorodiphenyltrichloroethane [DDT]), industrial chemicals (such as polychlorinated biphenyls [PCBs] and hexachlorobenzene [HCB]), and unintended by-products (such as dibenzodioxins and dibenzofurans) [63, 64] . The first epidemiological research reporting a relationship between dioxin and diabetes mellitus was published in 1997 [65] . By the time of the NTP workshop, more than 70 epidemiological studies had investigated the association between POPs and diabetes (Table 1) [10•, 13•] . Because of considerable heterogeneity across studies regarding exposure and outcome ascertainments, the NTP workshop review concluded that the data were insufficient to establish a causal relationship between POPs and diabetes. There was, however, suggestive evidence in support of a positive association among trans-nonachlor, dichlorodiphenyldichloroethane, DDT, dichlorodiphenyldichloroethane, PCBs, agent orange/ tetrachlorodibenzo-p-dioxin , miscellaneous organochlorine compounds, or POP mixtures and type 2 diabetes [10•, 13 •]. For brominated compounds and perfluoroalkyl acids, the NTP workshop review concluded that there was no positive pattern of associations. CS cross-sectional study; CO prospective cohort study; NCC nested case-control; NHL non-Hodgkin lymphoma study; NR not reported; FBG fasting blood glucose; OGTT oral glucose tolerance test; BDE bromodiphenylether congeners; DDT dichlorodiphenyltrichloroethane; DDE dichlorodiphenyldichloroethene; DDD dichlorodiphenyldichloroethane; PCB polychlorinated biphenyls; PeCB pentachlorobenzene; HCB hexachlorobenzene; HCH hexachlorocyclohexane; PeCDF pentachlorodibenzofuran; HxCDD hexachlorodibenzo-p-dioxin; HpCDD heptachlorodibenzo-p-dioxin; OCDD Octachlorodibenzo-p -dioxin; PCDD polychlorinated dibenzo-p-dioxin; PCDF polychlorinated dibenzo-furan; DL-PCB dioxin-like PCB; TeCCD tetrachorinated-dibenzo-p-dioxin; PeCDD pentachlorodibenzo-p-dioxin; TeCDF tetrachlorodibenzofuran; HxCDF hexachlorodibenzofuran; HpCDF heptachlorodibenzofuran; OCDF octachlorodibenzofuran; TEXB total effective xenoestrogen burden Our update review identified 11 additional publications meeting our inclusion criteria (Table 4) . The studies were conducted in populations from Japan [66, 73] , the U.S. [67, [70] [71] [72] 75 •], Sweden [68] , Finland [69] , and Spain [62, 74] . Three studies focused on PCB exposure [66, 67, 72] , and eight studies evaluated a broader spectrum of POPs [62, 68-71, 73, 74, 75•] . Nine studies were cross-sectional [62, 66, 67, [69] [70] [71] [72] [73] [74] , and two studies were prospective cohort studies [68, 75•] . Diabetes definitions combined self-reported physician diagnosis [62, 66, 67, [70] [71] [72] [73] [74] 75 •] and/or antidiabetic medication use [62, 68, 69] with FBG [62, 68-70, 72, 74] , OGTT [69] , or HbA1c [66, 71, 73] . Overall, a significant positive association was consistently shown between organochlorine compounds and type 2 diabetes in studies worldwide. The two prospective studies evaluated the association between baseline organochlorine levels and diabetes development over 5 [68] and 19 [75• ] years of follow-up, providing strong inferences about the temporal precedence [68, 75•] . One of the studies also conducted a meta-analysis of all prospective studies evaluating POPs and incident diabetes [75•] . The pooled OR was 2.0 (95 % CI: 1.13-3.53) for HCB and 1.70 (95 % CI: 1.28-2.27) for total PCBs [75•] . Two studies also analyzed the association between PCB exposure and insulin resistance, but no significant association was observed. This implies that PCBs may induce pancreatic β-cell dysfunction, although this hypothesis needs to be more thoroughly evaluated in human populations [67, 72] . In a population from Anniston, Alabama, the association between POPs and diabetes was significant only among women [70] . Additional research is needed to evaluate potential sex differences in diabetes susceptibility due to POP exposures.
For cross-sectional studies, reverse causality and disease progression bias could be important limitations. One longitudinal study found that diabetes may result in temporal increases in serum dioxin concentrations, especially among individuals with poor diabetes control [76] . A major challenge in POP research is the evaluation and identification of specific compounds. Most studies tested at least five POPs, but few studies have corrected for multiple testing [77] . Finally, standardization of POP measurement (e.g., wet vs. dry deposition, toxic equivalency [TEQ] vs. measured values), adjustment or not for lipid levels, and evaluation of confounders are ongoing challenges that require standardization in order to facilitate data comparison and metaanalysis. Overall, increasing and consistent evidence, including prospective studies [65, 68, 75•, 78-86] , supports the relationship between POPs and diabetes. Risk assessment of POPs should consider diabetes as a relevant outcome.
Research Needs-Epidemiologic Studies
Given the large number of studies evaluating the association between POPs and diabetes, additional studies following similar study designs are unlikely to further advance the science. Meta-analyses of individual congeners, of congeners grouped according to their activity (e.g., estrogenic, dioxin-like), and of overall levels are strongly needed. The information obtained from the meta-analyses could increase our understanding of the critical compounds. Dose-response metaanalyses could also be useful. The evaluation of the potential impact of the reduction of POP levels in diabetes risk is also critical to support the causality of the relationship.
Phthalate and Diabetes
Current Perspectives
Phthalates are a family of man-made compounds used as plasticizers that provide flexibility and durability of plastics such as polyvinyl chloride [87] . They are also used as solvents. The ubiquitous use of phthalate esters in plastics, personal care products such as cosmetics, medical devices, and food packaging leads to extensive exposure in general populations. In the U.S. general population, about 75 % of people have detectable phthalate metabolites in urine [88] . The first large epidemiological study linking phthalates and diabetes-related outcomes was published in 2007 using NHANES. Higher phthalates concentrations in urine were associated with increased abdominal obesity and insulin resistance [89] . Mechanistically, the close interplay between phthalates and peroxisome proliferatoractivated receptor-alpha and gamma (PPAR α and PPAR γ ) has been regarded as the main pathway to impairing both glucose metabolism and beta-cell function [90] [91] [92] . Phthalates can behave as an endocrine-disrupting chemical that directly activates PPAR γ and promotes adipogenesis [93] [94] [95] . However, the recent NTP workshop review suggested that there were insufficient data to reach conclusions on the role of phthalate and diabetes [10•].
We identified three epidemiological studies published after the NTP workshop in 2011 [87, 96, 97] (Table 5 ). The studies were conducted in Mexico [97] , Sweden [96] , and the U.S. [87] . Phthalate exposure was measured in the urine in two studies [87, 97] and in serum in one study [96] . Diabetes was defined on the basis of self-reported physician diagnosis and FBG in one study [96] and self-reported physician diagnosis in two studies [87, 97] . All studies were cross-sectional and consistently found borderline and/or statistically significant associations with some phthalates and diabetes. The estimated risks for total di-2-ethyl hexyl phthalate (DEHP) ranged from 1.43 [87] to 1.64 [97] and for mono-ethyl phthalate from 0.89 [87] to 1.28 [96] (median 1.02 [97] ). Two studies focused on women [87, 97] , and the other targeted an elderly population [96] , which limits the generalizability to general populations. Women might be more vulnerable to metabolic effects of phthalates, since they have higher urine concentrations of certain phthalates [98] . The reasons for higher phthalate concentrations among women are unknown [98] , but higher use of personal care products that contain phthalates could be involved [99] . No clear sex differences, however, have been found for blood phthalates [96, 98] . Given the lack of prospective evidence, the current evidence is suggestive but insufficient to support the relationship between phthalates and diabetes.
Research Needs-Epidemiologic Studies
The weaknesses in the current epidemiological evidence include a lack of prospective studies and the use of self-reported diabetes diagnosis in most studies. In addition to prospective studies, there is a need to evaluate exposure patterns and variation in phthalate biomarker concentrations over time, using longitudinal designs. Since most phthalates have relatively short half-lives in humans, more data are needed to determine the long-term stability/reproducibility of both urine and blood phthalates concentrations and the adequacy of those biomarkers to evaluate their relationship with chronic diseases [100] . Because phthalates are ubiquitous, reducing exposure is challenging from a public health practice perspective. Recently, the French government has passed a law to ban the use of tubes containing DEHP in pediatrics, neonatology, and maternity wards in hospitals [101] .
Bisphenol A and Diabetes
Current Perspectives BPA (2, 2-bis [4-hydroxyphenyl] propane) is widely used in polycarbonate plastic, epoxy resins, and food contact materials, leading to potential exposure through food [102] . It was estimated that over 8 billion pounds of BPA were produced, with over 100 tons released into the atmosphere each year [103, 104] . BPA exposure is ubiquitous, and more than 90 % of the U.S. population has detectable BPA in the urine [105] . Dietary exposure to BPA-contaminated food and beverages likely represents the major source of exposure for general populations [106] , although it is clear that we do not understand all the sources of exposure to BPA, as evidenced by findings in medical devices [107] and thermal paper [108] . Mechanistically, BPA is often described as having estrogenic activity, but it also displays other biological activities and should not be considered to act only as an estrogen or even a selective estrogen receptor modulator. Depending on the system studied and the dose, BPA may exert multiple cellular and tissue-type specific effects [102] . Experimental studies using BPA at environmentally relevant levels have supported the role of BPA in the development of obesity and diabetes through the inhibition of adiponectin and impairment of pancreatic beta cell regulation [109, 110] . However, evidence in humans is very limited and inconsistent. In 2011, the NTP 2011 workshop review did not make any conclusion on the relationship between BPA and diabetes, due to scarce evidence [10•] .
Following the NTP workshop review, four additional publications have been published [111] [112] [113] [114] (Table 6 ). These studies were all cross-sectional and conducted in representative populations from the U.S. [112, 113] , South Korea [114] , and Shanghai, China [111] . BPA exposure was measured in urine in all studies [111] [112] [113] [114] . Diabetes was defined by self-reported physician diagnosis in one study [114] and by combining self-reported physician diagnosis and/or antidiabetic medication use [111] [112] [113] with FBG [111, 112] or HbA1c [112, 113] . The two studies conducted in the U.S. based on NHANES 2003-2008 found estimated relative risks for diabetes of 1.08 per doubling of urine BPA concentration [113] and 1.68 in the highest quartile of BPA exposure to the lowest quartile [112] . In the NHANES study that evaluated the association between BPA and diabetes in each NHANES cycle separately [112, 113, 115] . The studies from South Korea and China did not observe a positive association between BPA and diabetes; however, these studies restricted their study population to participants older than 40 years [111, 114] . In the study from Shanghai, China, no clear dose-response relationship with diabetes was observed across BPA quartiles [111] ; however, BPA was significantly associated with obesity and insulin resistance [116] . The mean urine BPA concentration was lower in Shanghai, as compared with the studies in the U.S. and Korea. Although no significant association between BPA and diabetes was found in the South Korean study, urine BPA levels were significantly higher among female participants with diabetes 50-59 years of age and among urban residents [114] .
Several of the studies conducted stratified analyses to assess overweight/obesity as a modifying factor for diabetes [112, 113] or insulin resistance [116] . Overall, there was a trend for larger adjusted odds ratios in people with a normal body mass index (less than 24 or 25 kg/m 2 ), as compared with those considered overweight or obese. This suggests that the metabolic effects of being overweight or obese may overwhelm any effects of BPA on diabetes or insulin resistance [116] .
Given the lack of prospective evidence, the current epidemiological evidence is insufficient to support the relationship between BPA and diabetes. As was noted during the discussions from the 2011 NTP workshop, the findings from the in vivo studies in laboratory animals are supportive of an effect of BPA on insulin sensitivity and glucose homeostasis-in particular, suggesting a phenotype of insulin resistance. However, there are inconsistencies in the animal data. Understanding the basis for this lack of consistency is an important research need. Continued analysis of the existing literature is unlikely to clarify the sources of the observed heterogeneity because of variations in experimental design, such as route of administration, dose levels tested, Ca/NC case/non-case; CI confidence interval; CS cross-sectional study; NR not reported; FBG fasting blood glucose; OGTT oral glucose tolerance test; SBP systolic blood pressure; TG triglyceride; hs-CRP high-sensitivity C-reactive protein; ALT alanine aminotransferase; eGFR estimated glomerular filtration rate endpoints evaluated, life stage at exposure and assessment, species, sex, and diet.
Research Needs-Epidemiologic Studies
Since all studies have been cross-sectional, more large-scale prospective studies are needed to evaluate the relationship between BPA and diabetes. Appropriate adjustment for potential confounders is a major challenge in the evaluation of the association between BPA and diabetes. Since the main sources of BPA exposure are food and beverages in epoxy-coated cans, polycarbonate drinking bottles, or other BPA-related packages, populations that tend to use more processed and tinned food may have higher BPA exposure [102, 117] . Adjustment for those relevant dietary factors and for underlying socioeconomic factors is generally difficult. One factor that complicates conducting and interpreting epidemiological studies of BPA, especially cross-sectional studies, is that there is considerable within-person variability in urinary BPA concentrations [118] [119] [120] and, thus, a single spot urine sample may result in misclassification of BPA exposure. Other challenges in BPA epidemiologic research include BPA contamination of biospecimens that may occur during sample preparation or storage, background contamination from labware, and/or the analytical technique employed [121] .
Conclusion
Increasing evidence supports the role of environmental chemicals in diabetes development, including arsenic and other metals, POPs, phthalates, and BPA. An important advance in recent years has been the increased number of prospective studies, especially for arsenic and POPs. However, the number of prospective studies remains small, making it difficult to reach firm conclusions. Remaining questions include the evaluation of the dose-response relationship, the role of joint exposures, and effect modification with other comorbidities and genetic variants. Exposure and outcome assessment also remain critical aspects in study design to minimize misclassification. Exposure assessments with repeated measures are especially important, since such an approach would not only minimize measurement error, but also help characterize exposure patterns for environmental chemicals. Overall, the evidence is suggestive but not sufficient to infer a causal association between some environmental chemicals and diabetes outcomes.
